Skip to main content

Table 1 Demographic characteristics of patients in unweighted, Greedy-matching, and stabilized inverse probability of treatment–weighed samples

From: Comparisons of treatment satisfaction and health-related quality of life in patients with rheumatoid arthritis treated with tofacitinib and adalimumab

Characteristics (mean ± SD or n(%))

Total (n = 410)

Unweighted

Greedy matching

Stabilized IPTW

Tofacitinib

Adalimumab

SMD

Tofacitinib

Adalimumab

SMD

Tofacitinib

Adalimumab

SMD

(n = 281)

(n = 129)

(n = 139)

(n = 92)

(n = 226)

(n = 99)

Age

53.52 ± 12.19

54.47 ± 12.10

51.45 ± 12.18

0.249

52.73 ± 11.81

51.32 ± 11.50

0.121

53.56 ± 12.48

53.27 ± 11.35

0.025

Sex

 Male

54 (13.17)

40 (14.24)

14 (10.85)

0.102

16 (11.51)

8 (8.70)

0.094

28 (12.49)

15 (15.44)

0.085

 Female

356 (86.83)

241 (85.77)

115 (89.15)

123 (88.49)

84 (91.30)

197 (87.51)

82 (84.56)

Education

  ≤ high school

279 (67.89)

194 (69.04)

85 (65.89)

0.067

94 (67.63)

61 (66.3)

0.028

153 (67.98)

65 (67.55)

0.009

 College or more ≤ 

131 (32.11)

87 (30.96)

44 (34.11)

45 (32.37)

31 (33.7)

72 (32.03)

31 (32.45)

House annual incomea (10,000 won)b

  < 5000

277 (67.89)

191 (68.46)

86 (66.67)

0.038

94 (67.63)

66 (71.74)

0.090

153 (67.72)

69 (71.26)

0.077

 5000 ≤ 

131 (32.11)

88 (31.54)

43 (33.33)

45 (32.37)

26 (28.26)

73 (32.28)

28 (28.74)

Employment

 Employed

178 (45.64)

122 (46.04)

56 (44.8)

0.025

67 (48.2)

45 (48.91)

0.014

104 (45.89)

47 (48.41)

0.050

 Unemployed

212 (54.36)

143 (53.96)

69 (55.2)

72 (51.8)

47 (51.09)

122 (54.11)

50 (51.59)

BMI

23.43 ± 3.56

23.56 ± 3.54

23.13 ± 3.60

0.118

23.55 ± 3.52

23.30 ± 3.78

0.068

23.57 ± 3.58

23.56 ± 3.89

0.001

  1. a2 missing for house annual income
  2. b10,000 won = 8.24 USD
  3. IPTW inverse probability of treatment weighting, SD standard deviation, n number, SMD standardized mean differences, won, South Korean Won, BMI body mass index